Preoperative serum value of sialyl Lewis X predicts pathological nodal extension and survival in patients with surgically treated small cell lung cancer
Authors:
- 14 December 2011
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (8) , 818-824
Abstract
Background and objectives: We investigated various tumor markers in patients with surgically treated small cell lung cancer (SCLC) to identify the markers closely correlated to pathological staging and to predict survival by retrospective analyses.Methods: Reviewing database records between 1990 and 2007 revealed 36 patients with SCLC, that were grouped according to clinical and pathological stages. Receiver operating characteristic (ROC) curves were calculated for serum levels of various tumor makers to predict the pathological stage. The cut‐off value was calculated from the ROC curve of the significant marker. Survival in patient groups divided by the new cut‐off value was calculated.Results: Serum levels of various tumor makers were not significantly different between the pathological stage groups, except for serum sialyl Lewis X (SLX). ROC curve of SLX was significantly correlated to pathological stages (P = 0.0136). The calculated SLX cut‐off value was 25.1 U/ml, with 80% sensitivity and 70% specificity. Five‐year survival of patients selected by this new cut‐off was 82.5%, whereas that with the standard cut‐off (38.0 U/ml) was 55.9%.Conclusions: Serum SLX values were associated with pathological stage and survival after surgery in SCLC patients. J. Surg. Oncol. 2012; 105:818–824.Keywords
This publication has 10 references indexed in Scilit:
- The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2009
- Serum Sialyl Lewisx and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancerLung Cancer, 2007
- Clinical Value of Serum Cytokeratin 19 Fragment and Sialyl-Lewis X in Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2007
- High Serum Concentrations of Sialyl Lewisx Predict Multilevel N2 Disease in Non–Small-Cell Lung CancerAnnals of Surgical Oncology, 2006
- Non-Small Cell Lung Cancer: FDG PET for Nodal Staging in Patients with Stage I DiseaseRadiology, 2000
- Extent of mediastinal node metastasis in clinical stage I non-small-cell lung cancer: The role of systematic nodal dissection1Presented at the 8th World Conference on Lung Cancer, 10–15 August 1997, Dublin, Ireland.1Lung Cancer, 1998
- Elevated Serum Sialyl Lewis X-i Antigen Levels in Non-Small Cell Lung Cancer with Lung MetastasisRespiration, 1998
- Increased expression of sialyl Lewisx antigen is associated with distant metastasis in lung cancer patients: Immunohistochemical study on bronchofiberscopic biopsy specimensLung Cancer, 1998
- Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl Lewis X, and sialyl Lewis a in lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1994
- A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1989